JP2020506878A5 - - Google Patents

Info

Publication number
JP2020506878A5
JP2020506878A5 JP2019530506A JP2019530506A JP2020506878A5 JP 2020506878 A5 JP2020506878 A5 JP 2020506878A5 JP 2019530506 A JP2019530506 A JP 2019530506A JP 2019530506 A JP2019530506 A JP 2019530506A JP 2020506878 A5 JP2020506878 A5 JP 2020506878A5
Authority
JP
Japan
Prior art keywords
alkyl
ring
trek
haloalkoxy
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019530506A
Other languages
English (en)
Japanese (ja)
Other versions
JP7120549B2 (ja
JP2020506878A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2017/044975 external-priority patent/WO2018110669A1/en
Publication of JP2020506878A publication Critical patent/JP2020506878A/ja
Publication of JP2020506878A5 publication Critical patent/JP2020506878A5/ja
Application granted granted Critical
Publication of JP7120549B2 publication Critical patent/JP7120549B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019530506A 2016-12-15 2017-12-14 Trek(twik関連kチャネル)チャネルのアクチベータ Active JP7120549B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662434524P 2016-12-15 2016-12-15
US62/434,524 2016-12-15
PCT/JP2017/044975 WO2018110669A1 (en) 2016-12-15 2017-12-14 Activator of trek (twik related k+ channels) channels

Publications (3)

Publication Number Publication Date
JP2020506878A JP2020506878A (ja) 2020-03-05
JP2020506878A5 true JP2020506878A5 (enExample) 2022-03-28
JP7120549B2 JP7120549B2 (ja) 2022-08-17

Family

ID=62558996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019530506A Active JP7120549B2 (ja) 2016-12-15 2017-12-14 Trek(twik関連kチャネル)チャネルのアクチベータ

Country Status (4)

Country Link
US (2) US11046683B2 (enExample)
EP (1) EP3558992A4 (enExample)
JP (1) JP7120549B2 (enExample)
WO (1) WO2018110669A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016030690B1 (pt) 2014-06-27 2023-11-14 Nogra Pharma Limited Compostos moduladores do receptor de arila, composição farmacêutica compreendendo os mesmos e usos terapêuticos dos ditos compostos
WO2018232264A1 (en) * 2017-06-15 2018-12-20 The Board Of Regents Of The University Of Oklahoma Benzamide derivatives for inhibiting endoplasmic reticulum (er) stress
JP2022553284A (ja) * 2019-10-24 2022-12-22 小野薬品工業株式会社 Trek(twik関連k+チャネル)チャネル機能の阻害剤
CN114031601B (zh) * 2022-01-12 2022-03-18 南京桦冠生物技术有限公司 一种盐酸兰地洛尔的制备方法
US20250171405A1 (en) * 2022-02-23 2025-05-29 Biohaven Therapeutics Ltd. Pyrazolyl compounds as kv7 channel activators
US20250171429A1 (en) * 2022-02-23 2025-05-29 Biohaven Therapeutics Ltd. Pyrazolyl compounds as kv7 channel activators
MX2024010081A (es) * 2022-02-23 2024-08-27 Biohaven Therapeutics Ltd Compuestos de pirazolilo como activadores del canal de potasio dependientes de voltaje 7 (kv7).
CN114805233A (zh) * 2022-03-30 2022-07-29 华南理工大学 苯基四氮唑类xor抑制剂及其制备方法与应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783593A (en) * 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
US6417185B1 (en) 1998-06-19 2002-07-09 Chiron Corporation Inhibitors of glycogen synthase kinase 3
BR0010651A (pt) * 1999-05-17 2002-03-19 Novo Nordisk As Composto, uso de um composto, composição farmacêutica, e, método para o tratamento e/ou prevenção de distúrbios ou de doenças mediadas por uma ação antagonìstica de glucagon
DE19929787A1 (de) 1999-06-29 2001-01-04 Bayer Ag Neue 4-(2-Oxodihydrooxadiazinylphenyl)amide und ihre Verwendung
DE10060807A1 (de) * 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US7199147B2 (en) 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
MXPA04002404A (es) * 2001-09-14 2004-05-31 Novo Nordisk As Ligandos novedosos para los sitios hisb10zn2+ del hexamero de insulina en estado r.
GB0124936D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
RS53118B (sr) * 2003-02-26 2014-06-30 Sugen Inc. Aminoheteroaril jedinjenja kao inhibitori protein kinaze
PT1603917E (pt) 2003-03-14 2011-02-04 Medigene Ag Compostos heterocíclicos imunomoduladores
US20060160794A1 (en) * 2003-06-12 2006-07-20 Amegadzie Albert K Tachykinin receptor antagonists
JP5017103B2 (ja) 2004-06-17 2012-09-05 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 薬剤共結晶組成物および関連した使用方法
CA2588517A1 (en) 2004-12-01 2006-06-08 Devgen N.V. 5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the kv family
KR20070092297A (ko) * 2004-12-21 2007-09-12 데브젠 엔브이 Kv4 이온 채널 활성을 갖는 화합물
US8148535B2 (en) * 2005-10-21 2012-04-03 Merck Sharp & Dohme Corp. Potassium channel inhibitors
DE102006005861A1 (de) 2006-02-09 2007-08-23 Aicuris Gmbh & Co. Kg Substituierte Chinolone III
EP1987004A2 (en) 2006-02-16 2008-11-05 Boehringer Ingelheim International GmbH Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
CA2651871A1 (en) * 2006-05-10 2007-11-22 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2007138110A2 (en) 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
WO2007138112A2 (en) 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
CA2666539A1 (en) 2006-10-23 2008-05-02 Pfizer Inc. Substituted phenylmethyl bicyclocarboxyamide compounds
US7956216B2 (en) * 2006-12-21 2011-06-07 The Walter And Eliza Hall Institute Of Medical Research Alpha-helical mimetics
ATE461177T1 (de) 2007-03-23 2010-04-15 Icagen Inc Ionenkanal-hemmer
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
EP2020413A1 (de) 2007-08-02 2009-02-04 Bayer CropScience AG Oxaspirocyclische-spiro-substituierte Tetram- und Tetronsäure-Derivate
ES2400604T3 (es) 2007-08-17 2013-04-11 Icagen, Inc. Heterociclos como moduladores del canal de potasio
DE102007044277A1 (de) * 2007-09-17 2009-03-19 Grünenthal GmbH Substituierte Nicotinamid-Verbindungen und deren Verwendung in Arzneimitteln
EP2215054B8 (en) * 2007-11-13 2012-02-08 Evotec AG Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2009117421A2 (en) * 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CL2009000916A1 (es) 2008-04-17 2010-12-31 Glaxo Group Ltd Compuestos derivados de 2-trifluorometil-1h-indol-5-metilcarboxamida, moduladores del receptor nicotinico de acetilcolina alfa7 (nachr); composicon farmaceutica; y uso para el tratamiento del deterioro cognitivo y de un trastorno psicotico como esquizofrenia.
TW201000447A (en) 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
TW201000446A (en) 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
PE20140572A1 (es) 2008-06-05 2014-05-16 Janssen Pharmaceutica Nv Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
JP2012519682A (ja) 2009-03-03 2012-08-30 ファイザー・インク ガンマ−セクレターゼモジュレーターとしての新規フェニルイミダゾールおよびフェニルトリアゾール
TWI461197B (zh) * 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
TWI475020B (zh) 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
WO2011021645A1 (ja) 2009-08-19 2011-02-24 大日本住友製薬株式会社 2環性ウレア誘導体、またはその薬学的に許容される塩
JP2013028538A (ja) 2009-11-13 2013-02-07 Dainippon Sumitomo Pharma Co Ltd 新規アミド誘導体
KR101458006B1 (ko) 2010-10-18 2014-11-04 라퀄리아 파마 인코포레이티드 Ttx-s 차단제로서의 아릴아미드 유도체
DE102011101446A1 (de) 2011-05-10 2012-11-15 Aicuris Gmbh & Co. Kg Herstellung von "Dense Bodies" (DB)
EP2713722B1 (en) 2011-05-31 2017-03-15 Receptos, LLC Novel glp-1 receptor stabilizers and modulators
KR101476379B1 (ko) * 2011-11-30 2014-12-29 한국과학기술연구원 페녹시프로판올 유도체 및 이를 함유하는 약학적 조성물
US10214476B2 (en) 2011-12-30 2019-02-26 Ecole Nationale Superieure De Chimie De Clermont Ferrand Pain relief compounds
MX2014012491A (es) * 2012-04-18 2014-11-14 Grünenthal GmbH 4-aminobenzamidas sustituidas como moduladores de kcnq2/3.
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
JPWO2015012328A1 (ja) 2013-07-24 2017-03-02 武田薬品工業株式会社 複素環化合物
JP2017114765A (ja) 2014-04-25 2017-06-29 大正製薬株式会社 トリアゾリルで置換されたヘテロアリール化合物
JP6195684B2 (ja) 2014-06-03 2017-09-13 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd ピラゾール化合物及びt型カルシウムチャンネルブロッカーとしてのそれらの使用
JP6619758B2 (ja) 2014-07-03 2019-12-11 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 疾患を処置するためのgls1阻害薬

Similar Documents

Publication Publication Date Title
TWI730986B (zh) 抗真菌化合物方法
JP2010522709A5 (enExample)
JP2015500887A5 (enExample)
JP2005536475A5 (enExample)
EA016687B8 (ru) Производные циклопропиламида
JP2015528471A5 (enExample)
JP2014502641A5 (enExample)
JP2017505790A (ja) mIDH1阻害剤としてのベンズイミダゾール−2−アミン
JP2014505688A (ja) オキサジン誘導体および神経障害の処置におけるその使用
RU2010107892A (ru) Производные феноксипирролидина, их применение и фармацевтические композиции, содержащие их
JP2018534286A5 (enExample)
JP2017511339A5 (enExample)
JP2010522711A5 (enExample)
JP2015500223A5 (enExample)
JP2018505876A5 (enExample)
JP2019534310A5 (enExample)
JP2015535247A5 (enExample)
WO2017079753A1 (en) Lysine-specific histone demethylase as a novel therapeutic target in myeloproliferative neoplasms
JP2017502063A5 (enExample)
JP2019529460A5 (enExample)
JP2016537432A5 (enExample)
CN110325523B (zh) 作为缓激肽b1受体拮抗剂的羧酸芳族酰胺
CA3148794A1 (en) 4-amino-quinolines/-quinazolines that bind to tdp-43 for the treatment of amyotrophic lateral sclerosis and related disorders
JP2017525717A5 (enExample)
JP2018501261A5 (enExample)